Abstract - (2021) Volume 12, Issue 1
We introduced the hospital policy on the management of severe symptomatic hyponatraemia (SSH), with hypertonic saline (HS) of 1.8% and 5% saline in 2017. This is one of the few UK centres to offer this treatment, therefore the evidence is limited. The policy was based on European and American guidelines (1) (2). Objectives To study the adherence, and effectiveness, of this guideline in managing patients with SSH. Methods Patients were identified using the Biochemistry tracking system between 01/01/18 until 14/05/20. The terms - Hypona, sod, Hypertonic, 5%, 1.8% as were searched. The laboratory result system was used to identify hyponatraemic
Abstract
We introduced the hospital policy on the management of severe symptomatic hyponatraemia (SSH), with hypertonic saline (HS) of 1.8% and 5% saline in 2017. This is one of the few UK centres to offer this treatment, therefore the evidence is limited. The policy was based on European and American guidelines (1) (2). Objectives To study the adherence, and effectiveness, of this guideline in managing patients with SSH. Methods Patients were identified using the Biochemistry tracking system between 01/01/18 until 14/05/20. The terms - Hypona, sod, Hypertonic, 5%, 1.8% as were searched. The laboratory result system was used to identify hyponatraemic.
Standard 1: 11 patients had symptoms of hyponatraemia. They were confusion (6), somnolence (5), seizure (4), and vomiting (3). Other symptoms included muscle twitching, fatigue and nausea. SSH was suspected in 2/11 patients, but it was not the primary diagnoses. One patient was asymptomatic- the only patient with chronic hyponatraemia. Standard 2a/b: All patients identified were treated with 1.8% saline. None with 5% saline. Standard 2c: 7/12 patients overcorrected (there should be a 130mmol/L) their serum sodium. 1 patient self-discharged before this. The mean length of time to achieve this was 6.5 days In addition: 3 patients died. No deaths were attributed to treatment with 1.8% saline. Specifically, no patients developed central pontine myelinolysis Conclusions 1. Our audit showed symptomatic improvement in moderate and SSH, following.
Biography:
Devina Sharma is from Biochemistry, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Prescot Street, Liverpool, UK.
Speaker Publications:
“Retrospective audit on the use of hypertonic saline in the management of acute symptomatic hyponatraemia in hospitalized patients”.
5th International Conference on Digestive and Metabolic Diseases; Webinar - November 24, 2020.
Abstract Citation:
Devina Sharma, Retrospective audit on the use of hypertonic saline in the management of acute symptomatic hyponatraemia in hospitalized patients, Digestive Diseases 2020, 5th International Conference on Digestive and Metabolic Diseases; Webinar - November 24, 2020.
(https://digestivediseases.conferenceseries.com/abstract/2020/retrospective-audit-on-the-use-of-hypertonic-saline-in-the-management-of-acute-symptomatic-hyponatraemia-in-hospitalised-patients)
Citation: Devina Sharma, Retrospective audit on the use of hypertonic saline in the management of acute symptomatic hyponatraemia in hospitalized patients, Digestive Diseases 2020, 5th International Conference on Digestive and Metabolic Diseases; Webinar - November 24, 2020
Received: 22-Feb-2021 Published: 26-Feb-2021, DOI: 10.35248/2155-6156.21.12.e102
Copyright: Sharma D © 2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
